EGF and GHRP6 Co-Administration Attenuates Cognitive Decline and Modulates Neuroprotective Genes in Preclinical Mouse Models
Background
Cognitive decline is a debilitating hallmark of neurodegenerative diseases, including Alzheimer's disease, for which current therapies offer limited efficacy due to complex pathophysiology and challenges in delivering neuroregenerative agents. The combined therapy of epidermal growth factor (EGF) and growth hormone-releasing peptide 6 (GHRP6) has previously shown neuroprotective effects in models of brain ischemia and preliminary clinical safety. This study explores their potential to address the specific gaps in treating age-related and chemically-induced cognitive impairment by targeting pathways like oxidative stress, neuroinflammation, and synaptic plasticity.
Study Design
Researchers evaluated the therapeutic potential of EGF + GHRP6 co-administration in two preclinical models of cognitive impairment: (i) age-related decline and (ii) impairment induced by intracerebroventricular streptozotocin (STZ). C57BL/6 mice were used, distributed into three experimental groups, each comprising 14-15 animals per group. Cognitive and motor function was assessed using gait pattern analysis, the Y-maze test for spatial working memory, and the novel object recognition test. Differential gene expression associated with neuroprotection was analyzed using qPCR.
Results
Both aged and STZ-induced models successfully reproduced deficits in working and spatial memory, alongside altered expression of genes linked to oxidative stress, neuroinflammation, and synaptic plasticity. In aged animals, EGF + GHRP6 treatment significantly increased step length (p = 0.04). In the Y-maze forced alternation test, aged mice receiving EGF + GHRP6 made more visits to the novel arm than to familiar arm 1 (p = 0.001) or familiar arm 2 (p = 0.04), indicating improved spatial memory. Cognitive benefits were also evident in the STZ-induced model. > The STZ-EGF + GHRP6 group exhibited an alternation percentage significantly higher than the STZ-vehicle group (p = 0.03). Furthermore, EGF + GHRP6 treatment increased the expression of genes associated with antioxidant defense (Hmox1), synaptic plasticity (Creb1), and oligodendrocyte differentiation (Olig1), while concurrently reducing the expression of the pro-inflammatory gene Nfkb1.
Key Findings
- EGF + GHRP6 treatment increased step length in aged mice (p = 0.04).
- Aged mice treated with EGF + GHRP6 showed improved Y-maze performance (p = 0.001, p = 0.04).
- STZ-induced cognitive impairment was attenuated by EGF + GHRP6, with higher Y-maze alternation (p = 0.03).
- EGF + GHRP6 increased expression of
Hmox1,Creb1, andOlig1genes. - EGF + GHRP6 reduced expression of the pro-inflammatory gene
Nfkb1.
Why It Matters
This study provides compelling preclinical evidence that EGF + GHRP6 co-administration could be a viable neuroprotective strategy to mitigate cognitive decline in neurodegenerative conditions. For peptide users and biohackers, this highlights a potential novel combination for cognitive support, particularly in age-related contexts. While specific dosing and administration protocols are not detailed in this abstract, the observed molecular and behavioral improvements suggest a promising avenue for future research into cognitive enhancement and neurodegeneration prevention. Further studies are needed to translate these findings into human-applicable protocols, but the dual-model success strengthens the case for this combination.
egf
ghrp6
cognitive-decline
neuroprotection
neuroinflammation
oxidative-stress